1. Scrip

BeiGene Bags $750m, Sees China Reforms Creating New Opportunities

 
• By Brian Yang

A spectacular secondary offering will enable Beijing-based BeiGene to expand in both novel R&D and manufacturing in 2018, driven largely by an integrated China-global approach, its CFO says.

Money Wave

Nothing feels better than starting the New Year with a full arsenal.

BeiGene (Beijing) Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer